此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

氨基酸锌 (ZnAA) 与葡萄糖酸锌的代谢效果比较

2026年9月18日 更新者:University of California, Berkeley

空腹状态下氨基酸锌 (ZnAA) 与葡萄糖酸锌的代谢效果比较

Food consumption affects zinc metabolism within the body. Lowe and colleagues demonstrated that zinc is directed out of plasma and into tissues, such as into the liver, postprandially . It is likely that zinc absorbed with a meal is directed to the liver via the portal circulation whereas that zinc taken in the fasted state is more readily directed to peripheral blood plasma. Zinc taken with food is more likely to be bound to components of the food matrix and, therefore, it is not absorbed as efficiently by Zip4 ionic zinc transporters in the upper gastrointestinal tract. Some of the zinc in the food matrix may, however, be co-absorbed with amino acids over the whole length of the small intestine . Co-absorption of zinc with amino acids may explain the greater effects of zinc taken with food on omega-6 fatty acid desaturation . The investigators propose that this effect may be maximized by providing supplemental zinc complexed with amino acids. Since the zinc amino acid complex likely mimics the absorption and retention of zinc bound to protein in food, the investigators further propose that zinc, bound to amino acids taken in the fasted state will be directed into the cellular compartments more efficiently than zinc associated with gluconate.

The primary aim in this study is to determine whether providing a zinc amino acid complex has a greater effect on indices of essential fatty acid desaturation compared with zinc gluconate when the zinc complexes are taken in the fasting state.

The investigators hypothesize that taking a zinc amino acid (Zn-AA) complex in a fasted state daily for two weeks has a greater effect on the Fatty Acid Desaturase 1 (FADS1) activity compared with zinc gluconate. Also, if the uptake of ionic zinc gluconate into cellular compartments is reduced in comparison to Zn-AA because the zinc gluconate is retained in the plasma, two weeks of a daily zinc gluconate will have a greater effect on fasting plasma zinc concentrations compared to a Zn- AA complex.

研究概览

详细说明

Once the informed consent is obtained and the schedule is set with the participant, the participant will pick up their zinc bottle they will consume for the first two weeks and will start the study on the scheduled date.

Visit 1 (Week 1, Day 1): The participants will come to Morgan Hall fasting for their first blood draw visit. They will come to the clinic after an 8-hour fast and we will collect a blood sample. They will be instructed to take their zinc starting on day 2 every morning thirty minutes prior to having their regular breakfast and to write what they eat for breakfast in their breakfast log daily. They will take the given zinc for thirteen days (days 2-14).

Visit 2 (Week 2, Day 15): The participants will come to Morgan Hall after an 8-hour fast and the investigators will collect a second blood sample. Subjects will then be given instructions for visits three and four which will take place two weeks later to allow for a washout period between the crossover studies.

Visit 3 (Week 5, Day 1): The participants will come to Morgan Hall fasting for their third blood draw visit. They will come to the clinic after an 8-hour fast and the investigators will collect a blood sample. Subjects will be instructed to take the alternate zinc starting on day 2 every morning thirty minutes prior to having their regular breakfast and to record their breakfast in their breakfast log daily. They will take the given zinc for thirteen days (days 2-14).

Visit 4: (Week 6, Day 15): The participants will come to Morgan Hall after an 8-hour fast and the investigators will collect a final fourth blood sample. The subjects' breakfast logs will be collected at this time and their participation in the study will be completed.

Study diets:

Study subjects will receive a total of 26 days of zinc (13 days of one form prior to the washout period, and then 13 of the alternate form after). They will be provided with 13 days of zinc 30 mg zinc, as zinc gluconate, and 30 mg zinc, as a zinc amino acid complex, per day. They will be randomly assigned to which form of zinc they will take for the first two weeks, taking either zinc gluconate or zinc amino acid in a fasted state. All participants will be asked to take the zinc in the fasted state at least 30 minutes before their breakfast meal. The men will log their breakfast foods, the amounts consumed, and the time they ate breakfast every day. They will be asked to maintain a steady dietary pattern over the course of the two weeks as well as maintain a steady physical activity routine.

Fasting:

No food is allowed for an 8-hour period before any of the 4 visits requiring blood sampling. Water can and should be consumed during the fast to maintain hydration and to facilitate blood collection. Any other beverages besides water are not to be consumed during the fasting period.

Blood samples (week 1, day 1; week 2, day 15; week 5, day 1; week 6, day 15.) Participants will provide a total of 4 blood samples during the study. The blood sample will be drawn by inserting a needle into a vein in their arm. Each sample will be approximately 15 ml (or 1 tablespoon); a total of 60 ml (about 1/4 cup) will be drawn for the whole study.

Laboratory analysis of samples. Blood samples will be analyzed for their total zinc content by inductively coupled plasma - optical emission spectrometry (ICP-OES) and for FADS1 activity index along with other fatty acids by liquid chromatography with tandem mass spectrometry (LC-MS/MS).

研究类型

介入性

注册 (实际的)

26

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • California
      • Berkeley、California、美国、94720
        • University of California, Berkeley

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 50年 (成人)

接受健康志愿者

是的

有资格学习的性别

男性

描述

Inclusion Criteria:

  • Apparently healthy men (i.e., have no current health issues requiring medications or a specific diet)
  • 18 to 50 years of age
  • Body mass index between 18 and 30 kg/m2
  • Willing to take zinc supplements provided by the study for a total of four weeks

Exclusion Criteria:

  • History of heart disease, any inflammatory disorder including inflammatory bowel syndrome or arthritis, or any cancer treatment, or previously diagnosed with HIV
  • Smoking or alcohol abuse, use of illicit drugs
  • Any contraindication to venipuncture such as bleeding disorders or use of blood thinners
  • Those taking vitamins or supplements including minerals and omega oils, who cannot agree to stop taking the supplements two weeks prior to the study and for the duration of the study

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:基础科学
  • 分配:随机化
  • 介入模型:交叉作业
  • 屏蔽:四人间

武器和干预

参与者组/臂
干预/治疗
实验性的:Zinc Amino Acid

The zinc in the supplement is complexed with the amino acids lysine and glutamate.

A 30 mg zinc amino acid supplement is taken p.o. in the fasted state for 13 days.

实验性的:Zinc Gluconate

The zinc in the supplement is complexed with gluconate.

A 30 mg zinc gluconate supplement is taken p.o. in the fasted state for 13 days.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
FADS1 activity index
大体时间:Day 1 (baseline 1), day 15 (endpoint 1), day 29 (baseline 2), day 43 (endpoint 2)

The molar ratio (unitless) of arachidonic acid to dihomo-gamma-linolenic acid, i.e., fatty acid desaturase 1 (FADS1) product to precursor.

Day 1 (baseline 1), day 15 (endpoint 1), day 29 (baseline 2), day 43 (endpoint 2)

次要结果测量

结果测量
措施说明
大体时间
Fasted plasma zinc concentration
大体时间:Day 1 (baseline 1), day 15 (endpoint 1), day 29 (baseline 2), day 43 (endpoint 2)

The concentration of zinc in blood plasma (mg/dL) sampled following an overnight fast

Day 1 (baseline 1), day 15 (endpoint 1), day 29 (baseline 2), day 43 (endpoint 2)

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2024年1月22日

初级完成 (实际的)

2024年11月12日

研究完成 (实际的)

2024年12月30日

研究注册日期

首次提交

2024年3月29日

首先提交符合 QC 标准的

2024年3月29日

首次发布 (实际的)

2024年4月4日

研究记录更新

最后更新发布 (实际的)

2026年9月23日

上次提交的符合 QC 标准的更新

2026年9月18日

最后验证

2024年4月1日

更多信息

与本研究相关的术语

其他研究编号

  • 2022-07-15499

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

未定

IPD 计划说明

De-identified data on FADS1 activity index and plasma zinc concentration will be made available upon request.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅